These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 11742937)

  • 1. Community-acquired lower respiratory tract infections: etiology and treatment.
    Guthrie R
    Chest; 2001 Dec; 120(6):2021-34. PubMed ID: 11742937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [What is reliable in antibiotic therapy of inflammatory bronchopulmonary diseases?].
    Koehler U; Podszus T; von Wichert P
    Internist (Berl); 1998 Dec; 39(12):1264-72. PubMed ID: 10198833
    [No Abstract]   [Full Text] [Related]  

  • 3. A review of worldwide experience with sparfloxacin in the treatment of community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis.
    Finch RG
    Int J Antimicrob Agents; 1999 Jun; 12(1):5-17. PubMed ID: 10389642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoroquinolones for respiratory infections: too valuable to overuse.
    Williams JH
    Chest; 2001 Dec; 120(6):1771-5. PubMed ID: 11742900
    [No Abstract]   [Full Text] [Related]  

  • 5. New antibiotics for community-acquired lower respiratory tract infections: improved activity at a cost?
    Ball P
    Int J Antimicrob Agents; 2000 Nov; 16(3):263-72. PubMed ID: 11091046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.
    Appelbaum PC; Gillespie SH; Burley CJ; Tillotson GS
    Int J Antimicrob Agents; 2004 Jun; 23(6):533-46. PubMed ID: 15194123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sparfloxacin: a review.
    Schentag JJ
    Clin Ther; 2000 Apr; 22(4):372-87; discussion 371. PubMed ID: 10823360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of fluoroquinolones in respiratory tract infections: community acquired pneumonia.
    García-Rodríguez JA; Muñoz Bellido JL
    Int J Antimicrob Agents; 2000 Nov; 16(3):281-5. PubMed ID: 11091048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluoroquinolones in the management of community-acquired pneumonia.
    Albertson TE; Dean NC; El Solh AA; Gotfried MH; Kaplan C; Niederman MS
    Int J Clin Pract; 2010 Feb; 64(3):378-88. PubMed ID: 20456176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoroquinolones for respiratory infection: too valuable to overuse (and too valuable to misuse!).
    Weiss K; Tillotson GS
    Chest; 2002 Sep; 122(3):1102-3; author reply 1103. PubMed ID: 12226065
    [No Abstract]   [Full Text] [Related]  

  • 11. [Community acquired pneumonia; no reason to revise current Dutch antibiotic guidelines].
    Oosterheert JJ; Bonten MJ; Schneider MM; Hoepelman IM
    Ned Tijdschr Geneeskd; 2003 Mar; 147(9):381-6. PubMed ID: 12661455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.
    Balfour JA; Lamb HM
    Drugs; 2000 Jan; 59(1):115-39. PubMed ID: 10718103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of community-acquired pneumonia.
    Bartlett J
    Chemotherapy; 2000; 46 Suppl 1():24-31. PubMed ID: 10810210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis.
    Raz-Pasteur A; Shasha D; Paul M
    Int J Antimicrob Agents; 2015 Sep; 46(3):242-8. PubMed ID: 26092096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gatifloxacin in community-acquired respiratory tract infection.
    Sethi S
    Expert Opin Pharmacother; 2003 Oct; 4(10):1847-55. PubMed ID: 14521494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin.
    Landen H; Möller M; Tillotson GS; Kubin R; Höffken G
    J Int Med Res; 2001; 29(2):51-60. PubMed ID: 11393349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guiding Principles for the use of Fluroquinolones in Out-patient Community Settings of India: Panel Consensus.
    Vora A; Krishnaprasad K
    J Assoc Physicians India; 2017 Aug; 65(8):51-52. PubMed ID: 28799307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin.
    Simoens S; Decramer M
    Expert Opin Pharmacother; 2008 Jul; 9(10):1735-44. PubMed ID: 18570606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemifloxacin: a new, potent fluoroquinolone for the therapy of lower respiratory tract infections.
    File TM; Tillotson GS
    Expert Rev Anti Infect Ther; 2004 Dec; 2(6):831-43. PubMed ID: 15566328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights in the treatment by levofloxacin.
    File TM
    Chemotherapy; 2004; 50 Suppl 1():22-8. PubMed ID: 15319551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.